Tìm theo
Natalizumab
Các tên gọi khác (2) :
  • Anti-alpha4 integrin
  • Anti-VLA4
Thuốc giảm miễn dịch
Thuốc Gốc
Biotech
CAS: 189261-10-7
ĐG : Biogen Idec Inc. , http://www.biogenidec.com
Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Độ tan chảy
61 °C (FAB fragment), 71 °C (whole mAb)
Dược Lực Học : In multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells, and their counter-receptors present on endothelial cells of the vessel wall. The clinical effect of natalizumab in multiple sclerosis may be a secondary result of its blockade of the molecular interaction of a 4b 1-integrin expressed by inflammatory cells with VCAM-1 on vascular endothelial cells, and with CS-1 and/or osteopontin expressed by parenchymal cells in the brain. α4-integrin is required for white blood cells to move into organs, therefore, natalizumab prevents these immune cells from crossing blood vessel walls to reach affected organs thereby decreasing inflamation.
Cơ Chế Tác Dụng : Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006. Binds to the α4-subunit of α4b 1 and α4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s).
Dược Động Học :

▧ Volume of Distribution :
* 5.7 ± 1.9 L [Multiple Sclerosis (MS) Patients] * 5.2 ± 2.8 L [Crohn's Disease (CD) Patients]
▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system when bound to leukocytes.
▧ Half Life :
11 ± 4 days
▧ Clearance :
* 16 +/- 5 mL/hour [patients with MS who did not have PML receiving the repeat IV administration of a 300 mg dose] * 22 +/- 22 mL/hour [Patients with Crohn's Disease receiving the repeat IV administration of a 300 mg dose]
Chỉ Định : For treatment of multiple sclerosis.
Tương Tác Thuốc :
  • Abatacept Avoid combination due to enhanced adverse effects of natalizumab and the risk of infections.
  • ado-trastuzumab emtansine Avoid combination due to the increased risk of infection.
  • Antithymocyte globulin Avoid combination due to enhanced toxic effects of natalizumab.
  • Belatacept Avoid infection due to enhanced adverse effects of natalizumab and the risk of infections.
  • Belimumab Avoid combination due to enhance adverse effects of natalizumab such as the risk of concurrent infections.
  • Bleomycin Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
  • Brentuximab vedotin Avoid combination due to the increased risk of concurrent infection.
  • Canakinumab Avoid combination due to the increased risk of infection.
  • Carboplatin Immunosuppressants such as natalizumab may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
  • Carmustine Immunosuppressants such as carmustine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
  • Certolizumab pegol Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
  • Chlorambucil Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
  • Cisplatin Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.
  • Cladribine Immunosuppressants such as cladribine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.
  • Clofarabine Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab.
  • Etanercept Avoid combination due to enhanced adverse effects of natalizumab and increased risk of infections.
  • Gemtuzumab ozogamicin Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
  • Glatiramer Acetate Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
  • golimumab Avoid combination due to the increased chance of infection.
  • Homoharringtonine Avoid combination due to the increased risk of infection.
  • Ibritumomab Avoid combination due to increased adverse effects of natalizumab and increased risk of infections.
  • Infliximab Increase adverse effects of natalizumab. Avoid combination
  • Obinutuzumab Avoid combination due to enhanced adverse effects of natalizumab.
  • Omalizumab Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections.
  • Paclitaxel Avoid combination due to the increased risk of infection.
  • Pegaspargase Avoid combination because of increased immunosuppressants and risk of infections.
  • Tacrolimus Tacrolimus may increase the toxic/adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.
  • Temozolomide The immunosuppressant, Temozolomide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
  • Temsirolimus Temsirolimus may increase the toxicity of Natalizumab. Concomitant therapy should be avoided.
  • Teniposide The immunosuppressant, Teniposide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
  • Teriflunomide Avoid combination due to the increased risk of infection.
  • Thalidomide Thalidomide may increase the adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.
  • Thiotepa The immunosuppressant, Thiotepa, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
  • Tioguanine The immunosuppressant, Thioguanine, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
  • Tofacitinib Avoid combination due to the increased risk of infection.
  • Topotecan The immunosuppressant, Topotecan, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
  • Tositumomab The immunosuppressant, Tositumomab, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.
  • Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
  • Tretinoin Oral tretinoin may increase the adverse/toxic effects of Natalizumab. Concurrent therapy should be avoided.
  • Valrubicin Valrubicin may increase Natalizumab toxicity. Concurrent therapy should be avoided.
  • Vinblastine Concomitant Vinblastine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
  • Vincristine Concomitant Vincristine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
  • Vinorelbine Concomitant Vinorelbine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.
Liều Lượng & Cách Dùng : Solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00108
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/59075-730-15
PharmGKB
http://www.pharmgkb.org/drug/PA164747191
Wikipedia
http://en.wikipedia.org/wiki/Natalizumab
RxList
http://www.rxlist.com/cgi/generic/tysabri.htm
Drugs.com
http://www.drugs.com/cdi/natalizumab.html
... loading
... loading